Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial.

Kogame, Norihiro; Chichareon, Ply; De Wilder, Kenneth; Takahashi, Kuniaki; Modolo, Rodrigo; Chang, Chun Chin; Tomaniak, Mariusz; Komiyama, Hidenori; Chieffo, Alaide; Colombo, Antonio; Garg, Scot; Louvard, Yves; Jüni, Peter; G Steg, Philippe; Hamm, Christian; Vranckx, Pascal; Valgimigli, Marco; Windecker, Stephan; Stoll, Hans-Peter; Onuma, Yoshinobu; ... (2020). Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheterization and cardiovascular interventions, 96(1), pp. 100-111. Wiley-Blackwell 10.1002/ccd.28428

[img] Text
Kogame_et_al-2019-Catheterization_and_Cardiovascular_Interventions (1).pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

BACKGROUND The aim of this study was to investigate the impact of ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) for bifurcation lesions. METHODS GLOBAL LEADERS was a randomized, superiority, all-comers trial comparing 1-month DAPT with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy (experimental treatment) with standard 12-month DAPT followed by 12-month aspirin monotherapy (reference treatment) in patients treated with a biolimus A9-eluting stent. The primary endpoint was a composite of all-cause death or new Q-wave myocardial infarction (MI) at 2 years. RESULTS Among the 15,845 patients included in this subgroup analysis, 2,498 patients (15.8%) underwent PCI for at least one bifurcation lesion. The incidence of the primary endpoint was similar between the bifurcation and nonbifurcation groups (4.7 vs. 4.0%, p = .083). The experimental treatment had no significant effect on the primary endpoint according to the presence/absence of a bifurcation lesion (bifurcation: hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.51-1.07; nonbifurcation: HR: 0.90, 95% CI: 0.76-1.07, p for interaction = .343), but was associated with significant reduction in definite or probable stent thrombosis (p for interaction = .022) and significant excess of stroke (p for interaction = .018) when compared with the reference treatment. CONCLUSIONS After PCI for bifurcation lesions using 1-month of DAPT followed by ticagrelor monotherapy for 23 months did not demonstrate explicit benefit regarding all-cause death or new Q-wave MI as in the overall trial.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Valgimigli, Marco and Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1522-1946

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Amanda Valle

Date Deposited:

30 Aug 2019 14:52

Last Modified:

13 Jul 2020 01:30

Publisher DOI:

10.1002/ccd.28428

PubMed ID:

31410968

Uncontrolled Keywords:

Percutaneous coronary intervention antiplatelet treatment bifurcation lesion drug-eluting stents

BORIS DOI:

10.7892/boris.132771

URI:

https://boris.unibe.ch/id/eprint/132771

Actions (login required)

Edit item Edit item
Provide Feedback